<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03316300</url>
  </required_header>
  <id_info>
    <org_study_id>NTMT-03-A</org_study_id>
    <nct_id>NCT03316300</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2</brief_title>
  <official_title>A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurotech Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurotech Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety
      of the Renexus® implants in participants with macular telangiectasia type 2.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Change in Ellipsoid Zone (EZ) Area Loss</measure>
    <time_frame>Baseline through 24 months.</time_frame>
    <description>Rate of change in EZ area loss as measured by en face imaging by Spectral-Domain Optical Coherence Tomography (SD-OCT) in the study eye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Aggregate Sensitivity of Microperimetry</measure>
    <time_frame>Baseline through 24 months.</time_frame>
    <description>Renexus ® compared to sham relative to mean change in aggregate sensitivity of microperimetry within the EZ line break area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Reading Speed</measure>
    <time_frame>Baseline through 24 months.</time_frame>
    <description>Renexus® compared to sham relative to mean change in reading speed assessed using International Reading Speed Texts (IReST) cards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Eye Institute-Visual Function Questionnaire (NEI-VFQ)</measure>
    <time_frame>Baseline through 24 months.</time_frame>
    <description>Renexus® compared to sham relative to mean change in the NEI-VFQ near activities subscale score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Loss of Best-Corrected Visual Acuity (BCVA)</measure>
    <time_frame>Baseline through 24 months.</time_frame>
    <description>Number of participants with a loss in BCVA of 15 or more letters in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) distance chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Loss of Best-Corrected Visual Acuity (BCVA)</measure>
    <time_frame>Baseline through 24 months.</time_frame>
    <description>Proportion of participants with a loss in BCVA of 15 or more letters in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) distance chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment-Emergent Serious Adverse Event (SAE)</measure>
    <time_frame>Baseline through 24 months.</time_frame>
    <description>Number of participants with at least 1 treatment-emergent SAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Treatment-Emergent Serious Adverse Event (SAE)</measure>
    <time_frame>Baseline through 24 months.</time_frame>
    <description>Proportion of participants with at least 1 treatment-emergent SAE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Macular Telangiectasia Type 2</condition>
  <arm_group>
    <arm_group_label>Renexus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Renexus®</intervention_name>
    <description>Surgery to receive one Renexus® device implant.</description>
    <arm_group_label>Renexus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Non-penetrating sham procedure to mimic implant procedure.</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Participant must have at least one study eye with a positive diagnosis of MacTel Type
             2

          -  Participant must have an Inner Segment - Outer Segment Junction Line (IS/OS) Photo
             Receptor (PR) break in the study eye(s) and en face EZ (area of IS/OS loss) as
             measured by spectral-domain optical coherence tomography (SDOCT) between 0.16 mm^2 and
             2.00 mm^2

          -  Participant's best corrected visual acuity is 54 letter score or better (20/80 or
             better) as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart

        Key Exclusion Criteria:

          -  Participant received intravitreal steroid therapy for non-neovascular MacTel within
             the last 3 months

          -  Participant has ever received intravitreal anti-vascular endothelial growth factor
             (VEGF) therapy in the study eye or has, within the past 3 months, received
             intravitreal anti-VEGF in the fellow eye

          -  Participant has evidence of ocular disease other than MacTel that, in the judgment of
             the examining physician, may confound the diagnosis, procedures or outcome of the
             study

          -  Participant was a study participant in any other clinical trial of an intervention
             (drug or device) within the last 6 months

          -  Participant is pregnant or breastfeeding

          -  Participant has a chronic requirement (eg ≥ 4 weeks at a time) for ocular medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Chew, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Eye Institute (NEI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alline Lelis</last_name>
    <phone>(401) 495-2388</phone>
    <email>a.lelis@neurotechusa.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scripps Clinic Carmel Valley Ambulatory Surgery Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Lin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Global Research Foundation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khaled Tawansy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jules Stein Eye Institute / David Geffen School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Hubschman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Do, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bay Area Retina Associates</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Southern Colorado, P.C.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Rich, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Retina and Macular Disease</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Hamilton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Associates of New Orleans</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanislav Zhuk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institute of Health</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry Wiley, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cumberland Valley Retina Consultants</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David J Warrow, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Associated Retinal Consultants, P.C.</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Capone Jr., MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arshad Khanani, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vitreous Retina Macula Consultants of New York</name>
      <address>
        <city>Manhattan</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Cleveland, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence J. Singerman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tulsa Retina Consultants</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Freisberg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charles Retina Institute</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Charles</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeastern Retina Associates, PC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph M. Googe, Jr., MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary E. Fish</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah John A. Moran Eye Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul S. Bernstein, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lions Eye Institute</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Constable, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Gaudric</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Charbel Issa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Egan</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 3, 2017</study_first_submitted>
  <study_first_submitted_qc>October 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ciliary Neurotrophic Factor (CNTF)</keyword>
  <keyword>Macular Telangiectasia (MacTel)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

